LLY

965.5

+4.67%↑

JNJ

187.39

+0.59%↑

UNH

319.05

-1.56%↓

NVS

126.74

+0.36%↑

ABT

125.72

-0.37%↓

LLY

965.5

+4.67%↑

JNJ

187.39

+0.59%↑

UNH

319.05

-1.56%↓

NVS

126.74

+0.36%↑

ABT

125.72

-0.37%↓

LLY

965.5

+4.67%↑

JNJ

187.39

+0.59%↑

UNH

319.05

-1.56%↓

NVS

126.74

+0.36%↑

ABT

125.72

-0.37%↓

LLY

965.5

+4.67%↑

JNJ

187.39

+0.59%↑

UNH

319.05

-1.56%↓

NVS

126.74

+0.36%↑

ABT

125.72

-0.37%↓

LLY

965.5

+4.67%↑

JNJ

187.39

+0.59%↑

UNH

319.05

-1.56%↓

NVS

126.74

+0.36%↑

ABT

125.72

-0.37%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Open

9.09 3.41

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.66

Max

9.47

Belangrijke statistieken
By Trading Economics
Inkomsten	453K -27M
Winstmarge	-2,027.003
Werknemers	81
EBITDA	408K -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+55.87% upside

Dividenden
By Dow Jones
Volgende Winsten	12 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	393M 587M
Vorige openingsprijs	5.68
Vorige sluitingsprijs	9.09

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 nov 2025, 21:36 UTC

Winsten

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 nov 2025, 21:22 UTC

Winsten

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 nov 2025, 00:00 UTC

Marktinformatie

India Inflation Poised to Hit New Low -- Market Talk

9 nov 2025, 23:47 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 nov 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 nov 2025, 21:05 UTC

Winsten

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 nov 2025, 21:04 UTC

Winsten

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 nov 2025, 21:03 UTC

Winsten

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 nov 2025, 20:49 UTC

Winsten

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 nov 2025, 20:49 UTC

Winsten

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 nov 2025, 20:45 UTC

Winsten

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 nov 2025, 20:45 UTC

Winsten

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 nov 2025, 20:42 UTC

Winsten

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 nov 2025, 20:42 UTC

Winsten

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 nov 2025, 20:41 UTC

Winsten

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 nov 2025, 20:41 UTC

Winsten

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 nov 2025, 20:39 UTC

Winsten

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 nov 2025, 20:39 UTC

Winsten

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 nov 2025, 20:38 UTC

Winsten

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 nov 2025, 20:38 UTC

Winsten

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 nov 2025, 20:38 UTC

Winsten

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 nov 2025, 13:10 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 03:50 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Winsten

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Winsten

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q EPS $9.89 >CSU.T

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

55.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.67 USD 55.87%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.